Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Kinetics Medical Fund No Load Class (MEDRX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital. The fund is a non-diversified fund that invests all of its investable assets in the Medical Portfolio- a series of Kinetics Portfolios Trust. The Portfolio invests at least 80% of its net assets plus any borrowings for investment purposes in common stocks- convertible securities- warrants- and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research- pharmaceutical and medical technology industries and related technology industries- with an emphasis toward companies engaged in cancer research and drug development. It is non-diversified.


1 month+2.79% 3 years+2.33%
3 months-1.46% 5 years+12.59%
1 year+14.30% Since inception+9.17%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+12.59%+17.28%
Expense ratio2.08%1.32%
Risk 5 year sharpe ratio0.921.11
Net assets$19.4M$3.0B
Average market cap$70.4B$9.3B
Average P/E24.521.8
Portfolio turnover0%0%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyKinetics
Fund manager & tenureBruce Abel / 18 Years
Minimal initial investment$2,500.00
Minimum IRA investment$2,500.00


U.S. stock67.13%
International stock26.81%
Fixed income0.05%
Top 5 Sectors
Portfolio weighting
Healthcare 94.65%
Industrial materials 4.23%
Business service 1.12%
Telecommunication 0.01%
Consumer goods 0.00%
Top 10 Holdings
Portfolio weighting
LLY Eli Lilly and Co7.81%
PFE Pfizer7.38%
BMY Bristol-Myers Squibb7.36%
SNY Sanofi5.99%
NVS Novartis5.78%
BIIB Biogen5.65%
JNJ Johnson & Johnson5.63%
ABBV AbbVie5.55%
ALKS Alkermes Plc5.38%
CELG Celgene4.91%